Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children ...

The U.S. Food and Drug Administration (USFDA) on Friday approved Merilog as biosimilar to Novolog (insulin aspart) for the ...

The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric ...

The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

pen fill cartridge Novolog Mix 70/30 pen fill cartridge (Novo Nordisk) 14 days Prescribing information 70% insulin aspart protamine suspension and 30% insulin as part injection (rDNA origin ...

Ellison says the settlement requires Novo Nordisk to provide insulin products—including Novolog, Tresiba ... prescription (3 vials or 2 packs of pens) for customers paying with cash.

For five years, insulin manufacturer Novo Nordisk agrees to cap out-of-pocket cost of its insulin treatments at $35 per month, and provide free insulin to the neediest Minnesotans.

The biosimilars – which will be interchangeable with Sanofi's Lantus (insulin glargine), Novo Nordisk's Novolog (insulin aspart ... than $55 for a box of five pen cartridges – which Civica ...

Novo Nordisk's Novolog, and Lilly's Humalog – by 2024. The company said its products will cost no more than $30 per vial or $55 for five pen cartridges, adding that compares to around $329 per ...